[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625996":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":33,"responsibleParty":74,"collaborators":76,"id":80,"slug":10,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":10,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":10,"enrollmentInfo":88,"targetDuration":91,"studyType":92,"phases":10,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":100,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tongue Dysphagia Oropharyngeal Cancer",null,"Patients with Oropharyngeal cancer who have received Iltamiocel as part of REVIVE Clinical Study",[13],"Other: Other: No Intervention (subjects were previously treated with Iltamiocel). This is a observational study and all participants will be observed with no intervention.",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Other: No Intervention (subjects were previously treated with Iltamiocel). This is a observational study and all participants will be observed with no intervention.","Participants are followed observationally to collect long-term safety and effectiveness data after prior receipt of iltamiocel in the separate Revive clinical trial; no intervention is administered as part of this registry. Long-term safety outcomes and efficacy will be separated in analysis \\& reporting",[9],[20],{"name":21,"affiliation":5,"role":22},"Peter Belafsky, MD","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Randev Sandhu, BS","CONTACT","916-734-2863","rssandhu@health.ucdavis.edu",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Johnathon Anderson, PhD","916-734-2801","joanderson@health.ucdavis.edu",[34,57],{"facility":35,"status":10,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"UC Davis Medical Center","Sacramento","California","95817","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-121.4944,38.58157,{"lat":45,"lon":44},[48,50,54,55],{"name":21,"role":26,"phone":31,"phoneExt":10,"email":49},"pcbelafsky@health.ucdavis.edu",{"name":51,"role":26,"phone":52,"phoneExt":10,"email":53},"Maggie Kuhn, MD","916734-2801","makuhn@health.ucdavis.edu",{"name":21,"role":22,"phone":10,"phoneExt":10,"email":10},{"name":51,"role":56,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"facility":58,"status":10,"city":59,"state":37,"zip":60,"country":39,"countryCode":40,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"UC SanFrancisco Medical Center","San Francisco","94115",{"type":42,"coordinates":62},[63,64],-122.41942,37.77493,{"lat":64,"lon":63},[67,71],{"name":68,"role":26,"phone":69,"phoneExt":10,"email":70},"Clark Rosen, MD","415-885-7700","clark.rosen@ucsf.edu",{"name":72,"role":26,"phone":69,"phoneExt":10,"email":73},"Yue Ma, MD","yue.ma@ucsf.edu",{"type":75,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[77],{"name":78,"class":79},"Cook MyoSite","INDUSTRY","100625996",false,"NCT07429890","REVIVE Prospective Registry Cohort Study","Prospective Observational Long-Term Safety and Effectiveness Registry of Patients Who Have Received Iltamiocel as Part of REVIVE Clinical Study in Patients With Tongue Dysphagia Resulting From the Treatment of Head and Neck Cancer","Inclusion Criteria:\n\n* Participants who have received iltamiocel as part of participation in the REVIVE clinical study for males and females with tongue dysphagia (TD) are eligible, provided the following criteria are fulfilled:\n\n  * Has completed the Month 24 visit in the REVIVE study.\n  * Has received iltamiocel as part of the blinded portion of the REVIVE study.\n  * Must be willing and able to comply with the study procedures, is able to understand all study requirements and must agree to read and sign the informed consent form prior to any study-related procedures.\n\nExclusion Criteria:\n\n* The following criteria will exclude participants from participation:\n\n  * Has received placebo as part of the blinded portion of the REVIVE study.\n  * Unable or unwilling to provide informed consent.\n  * Not available for, or willing to comply with the follow-up evaluations as required by the protocol.","ALL","18 Years",{"count":89,"type":90},31,"ESTIMATED","5 Years","OBSERVATIONAL","The main purpose of this registry is to collect observational, long-term safety and effectiveness data in participants who have received iltamiocel as part of the blinded portion of the REVIVE clinical study.",[95],"Oropharyngeal Dysphagia",[97,98,99],"Tongue","Dysphagia","Autologous","NOT_YET_RECRUITING","2026-06-16",{"date":103,"type":104},"2026-06-18","ACTUAL",{"date":106,"type":90},"2026-08-30",{"date":108,"type":90},"2032-06-30",{"name":5,"class":6},2]